Covid-19: Pfizer forecasts $ 36 billion in annual revenue for 2021

Pharmaceutical company Pfizer is making record profits with its Covid-19 vaccine.

DOMINICK REUTER AFP / File

Text by: RFI Follow

1 min

The pharmaceutical group Pfizer saw its sales climb and this Tuesday raised its annual sales forecast for its Covid-19 vaccine by 7.5%.

In the third quarter, Pfizer more than doubled its total sales to just over $ 24 billion.

The vaccine alone has brought in nearly $ 13 billion. 

Advertising

Read more

The more the weeks go by, the more sales reach dizzying records.

Pfizer has once again revised upwards its annual sales forecasts for Cominarty, its vaccine against Covid-19, developed in partnership with

.

The two companies which have already produced 2.6 billion, of which two billion have been distributed in 152 countries, plan this year to produce a total of three billion doses, at least one billion of which are intended for underprivileged countries.

Third dose and childhood vaccination

With the increase in vaccination campaigns, but also the commitments of a third dose in some countries, and the possibility of vaccinating children, Pfizer announces for 2021 annual revenues of $ 36 billion, against 33 billion and a half dollars in its previous predictions.

The American authorities who gave the

, have already ordered 115 million doses. 

According to the CEO of the group, Albert Bourla, 75% of the turnover generated by the vaccine was outside the United States.

He specifies that the group is continuing to expand thanks to new agreements around the world.

Newsletter

Receive all international news directly in your mailbox

I subscribe

Follow all the international news by downloading the RFI application

google-play-badge_FR

• Coronavirus

• Vaccines

• Economy

• Health and medicine